<DOC>
	<DOCNO>NCT00055263</DOCNO>
	<brief_summary>The purpose study : - Test safety DN-101 patient advanced malignancy - Understand fast body absorbs , process , eliminate DN-101 - Determine high dose DN-101 well tolerate cancer patient - Learn fast body absorbs , process , eliminate DN-101 compare approve product</brief_summary>
	<brief_title>A New Formulation Calcitriol ( DN-101 ) Patients With Advanced Malignancies</brief_title>
	<detailed_description>Calcitriol , low dos , approve FDA use patient chronic renal failure . However , much high dos calcitriol need possible anti-cancer effect . DN-101 new capsule contain 30 time amount calcitriol find currently available calcitriol capsule . In order take amount calcitriol equivalent 1 capsule DN-101 , cancer patient would need swallow 30 pill approve , low dose formulation . DN-101 pill contain calcitriol , chemical relate vitamin D immediately active body . The natural vitamin D find dairy product typical vitamin pill , must chemically change liver kidney calcitriol active . High dos calcitriol anti-cancer effect test animal . DN-101 may anticancer effect kind cancer .</detailed_description>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Inclusion Criteria Patients must meet follow inclusion criterion eligible participation study : Patients advance solid tumor malignancy Patients prostate cancer eligible 1 ) prostatectomy radiation therapy rise PSA , 2 ) androgen sensitive prostate cancer hormone therapy , 3 ) androgen independent prostate cancer fail hormone therapy Patients type malignancy require fail least one potentially effective therapy prior study entry Life expectancy &gt; 3 month Age &gt; 18 year The following laboratory result : Adequate hematologic function Adequate renal function Adequate liver function Negative urine pregnancy test ( female childbearing potential ) Willingness use effective contraception male females throughout treatment period least 2 month follow treatment Signed informed consent form Exclusion Criteria Patients meet follow exclusion criterion enrol study : Significant active medical illness ( current cancer ) opinion investigator would preclude protocol treatment History cancerrelated hypercalcemia , know hypercalcemia , vitamin D toxicity Uncontrolled heart failure Kidney stone ( calcium salt ) within past 5 year Prior investigational therapy within past 30 day Prior use calcitriol within past 3 month know hypersensitivity calcitriol Concurrent active treatment cancer exception treatment androgenindependent prostate cancer Excluded concomitant medication : calcium magnesiumcontaining antacid , bileresin binder , bisphosphonates , calcium supplement ; ketoconazole related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>advanced solid tumor malignancy</keyword>
</DOC>